Fax: (617) 632-2933
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era
Findings from a large national database
Article first published online: 17 OCT 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 11, pages 2944–2951, 1 June 2012
How to Cite
Kumar, A., Vanderplas, A., LaCasce, A. S., Rodriguez, M. A., Crosby, A. L., Lepisto, E., Czuczman, M. S., Nademanee, A., Niland, J., Gordon, L. I., Millenson, M., Zelenetz, A. D., Friedberg, J. W. and Abel, G. A. (2012), Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era. Cancer, 118: 2944–2951. doi: 10.1002/cncr.26588
Fax: (617) 632-2933
- Issue published online: 18 MAY 2012
- Article first published online: 17 OCT 2011
- Manuscript Accepted: 23 AUG 2011
- Manuscript Revised: 16 AUG 2011
- Manuscript Received: 25 JUL 2011
- diffuse large B-cell lymphoma;
- central nervous system prophylaxis;
- propensity score analysis;
- health services research
Little is known about the utility of central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. The objective of this study was to characterize patterns of CNS prophylaxis for patients who received combined rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy using the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes Database, a prospective cohort study that collects clinical and outcomes data for patients at 7 participating centers.
Patients who were eligible for this analysis presented with newly diagnosed DLBCL between January 2001 and July 2008, had no evidence of baseline CNS disease, and had received R-CHOP within 180 days of diagnosis. The authors assessed incidence and covariates of prophylaxis, prophylaxis modality, and, using propensity score analysis, outcomes such as overall survival.
Of 989 eligible patients, 117 received CNS prophylaxis (11.8%), most intrathecally (71.8%). Involvement of bone marrow, other high-risk site, >1 extranodal site, higher International Prognostic Index score, and higher stage were associated individually with the receipt of prophylaxis (all P < .0001). At a median follow-up of 2.5 years, there were 20 CNS recurrences (2% [95% confidence interval, 1.1%-2.9%]) among all patients, and overall survival was not affected by prophylaxis.
Given the overall low rate of CNS recurrence and lack of prophylaxis-associated survival benefit, the current data called into question the practice of CNS prophylaxis in the rituximab era. Cancer 2011. © 2011 American Cancer Society.